N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=5 BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Non Small Cell Lung Cancer With Bone Metastatses
Primary: Number of Symptomatic Skeletal Events (SSE) in Patients Receiving Xofigo With NSCLC and Bone Metastases — 1 Number of participants experiencing SSE
Phase 3 N=261 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Breast Cancer · Lung Cancer · Metastatic Cancer
Primary: Time to Development of a Malignant Skeletal-related Events (SRE) — 29.9; 27.4 months — p=0.844
Phase 2 N=44 S0916, MLN1202 in Treating Patients With Bone Metastases
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: uNTX Response Rate at 43 Days — 14 percentage of participants
Phase 2 N=114 Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Cancer
Primary: Cohort 1 - NaF PET/CT vs 99mTc-MDP Bone Scintigraphy — 10; 0; 0 Participants
Phase 2 N=12 Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases
Breast Cancer · Bone Metastases
Primary: Time to Progression — 317 Days
Phase 3 N=437 A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
Non-Small-Cell Lung Cancer
Primary: Progression-Free Survival — 9.0; 11.3 Months
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
N/A N=102 Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis
Malignant Neoplasm · Metastatic Malignant Neoplasm in the Bone · Pain
Primary: Re-Treatment Rates - Arm 1 (8 Gy x 1) vs. Arm 2 (8 Gy x 2) — 3; 3; 19; 17 Participants — p=0.8325
N/A N=115 ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
Bone Metastases · Multiple Myeloma
Primary: Number of Responders — 54; 6 Participants
Phase 2 N=60 To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
Nasopharyngeal Cancer
Primary: Comparing the Level of Urinary N-telopeptide (uNTx) in the Two Arms . — 75; 94; 29; 88 nM /mM — p=0.370
Phase 2 N=45 Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer
Breast Cancer
Primary: Response of Bone Marrow Micrometastases — -4.5 DTCs/mL
Phase 2 N=37 Cabozantinib in Advanced Solid Malignancies
Lung Cancer · Solid Tumor (Not Breast or Prostate Cancers)
Primary: Number of Participants With Bone Bio-marker Response — 13; 9; 8 Participants
N/A N=15 Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma
Prostate Adenocarcinoma
Primary: True Positive and False Positive Rates of F-18 Fluciclovine-PET/CT Findings Compared to Bone Biopsy — 13; 7; 6 participants
N/A N=850 Single vs Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases
Metastatic Cancer · Pain
Primary: Pain Relief Measured by the Brief Pain Inventory at 2 Months After Treatment — 28.0; 32.0 percentage of participants — p=0.03
Phase 3 N=3,323 Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer
Breast Cancer
Primary: Disease Free Survival. — 81.0; 79.6 percentage of patients
Phase 4 N=6 Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement
Osteoporosis
Primary: Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck — 100 percentage of participants
Phase 2 N=36 Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
Anatomic Stage IV Breast Cancer AJCC v8 · Estrogen Receptor Positive · HER2/Neu Negative
Primary: Response Rate — 29; 6 Participants
N/A N=2,165 Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
Phase 3 N=485 A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors
Fractures, Bone
Primary: Percent Change (Chg) From Baseline (BL) to Week (Wk)13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr)…
Phase 2 N=43 A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)
Breast Cancer · Metastatic Bone Disease
Primary: Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen (u-NTx) at Week 4 — -73; -77 Percentage change
N/A N=54 Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer
Recurrent Prostate Cancer
Primary: Number of Eligible Patients With Positive CT Scan/Bone Scan, MRI and PET Scan. — 0; 0; 12; 17 Participants
Phase 3 N=78 Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
Hematological Malignancies
Primary: Percentage Change in Bone Mineral Density From Baseline to 6 and 12 Months — 0.06; -2.61; -3.63; -4.85 Percentage change
N/A N=12 Effect of High Doses of Radiation on Bone Structure and Metabolism
Malignant Bone Tumors
Primary: Change in Bone Mineral Density (Tb. BMD) — 4.5; -39.3; -8.7; -54.7 mg/cm^3
N/A N=63 Comparing Synthetic Bone Alone Versus Synthetic Bone With Bone Marrow in Bone Lesions
Bone Diseases
Primary: Resorption of Graft Material (GR) Compared at 24 Months — 51; 47 percentage of resorption — p=<0.01
N/A N=81 Safety and Efficacy Study of Treatment of Pathological Fractures in Humerus
Humerus Fracture Metastatic Bone Disease
Primary: Change in Pain — -52.7 units on a scale — p=0.615
Phase 3 N=18 Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer
Castrate-resistant Prostate Cancer
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) and Deaths — 11; 7; 7; 4 participants
Phase 1 N=23 Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
Solid Tumor · Osteosarcoma
Primary: Dose Escalation Part: Number of Dose-Limiting Toxicities (DLTs) at Each Dose Level on Cycle 1 — 0; 2 Number of DLTs
Phase 2 N=35 Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis
Metastatic Cancer · Pain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Pain Response as Measured by VAS at 3 Months — 8; 12; 1 Participants
N/A N=73 Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases
Pain · Neoplasm Metastasis · Bone Metastasis of Diverse Origins
Primary: Change From Baseline in Worst Pain Scores as Assessed by the Brief Pain Inventory-Short Form (BPI-SF) at Week 8 — 7.26; -2.61 score on a scale — p=0.0746